FDA Grants Fast Track Designation For DB102 in Patients with Newly-Diagnosed Glioblastoma (GBM)

SAN DIEGO, July 17, 2020 -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials